Followers | 2771 |
Posts | 77901 |
Boards Moderated | 1 |
Alias Born | 05/10/2007 |
Sunday, May 07, 2017 5:31:11 PM
Eric Ankerud, Ocular Therapeutix, Inc. - EVP, Regulatory, Quality, and Compliance [8]
--------------------------------------------------------------------------------
Good morning, Ken, thanks for the question. FDA completed their re-inspection of our facility as part of the NDA review late yesterday afternoon. As Amar mentioned 483 was issued.
We were pleased during the re-inspection that the FDA investigator was able to confirm our corrective action plan from prior observations and indicated that there was no further follow-up necessary to close out those issues. This was a new investigator, not the same investigator from prior inspections, and their primary focus in the 483 relates to a particulate matter issue as part of our manufacturing process. The issue relates primarily to completion of an investigation that we have underway in regard to the particulate matter, solidifying specifications for in-process 100% visual inspection of our inserts as well as enhancing our operator training.
We feel quite comfortable that we have the situation under control. And we are preparing responses to the 483 as of this morning in anticipation of responding within 15 calendar days to the agency. In addition to the particulate matter issue FDA raised a couple of observations in regard to analytical method testing to be completed as well as some other issue related to quality oversight of batch records.
So in summary, we believe that each of the observations raised by FDA during this continuous improvement review of our fully developed manufacturing process are handlable and will be resolved in our response to FDA. We are also pleased that the collaborative nature of our NDA review has continued between the various offices of FDA, and we are marching toward that PDUFA date and expect that we can resolve the 483 issues in a timely manner.
Donald Ellis, JMP Securities - Analyst [11]
--------------------------------------------------------------------------------
Thank you and good morning guys. Regarding the 483s, will there be a requirement for a re-inspection?
And then my second question is regarding the C code pass-through. What gives you comfort that a pass-through code will be granted for this product?
--------------------------------------------------------------------------------
Amar Sawhney, Ocular Therapeutix, Inc. - President, CEO & Chairman [12]
--------------------------------------------------------------------------------
So I will let Eric answer the question on the 483. And then Andy, maybe you can weigh in after that on the commercial stuff.
--------------------------------------------------------------------------------
Eric Ankerud, Ocular Therapeutix, Inc. - EVP, Regulatory, Quality, and Compliance [13]
--------------------------------------------------------------------------------
As a result of the completion of the re-inspection yesterday afternoon there is no indication of a Andrew Berens, Morgan Stanley - Analyst [23]
--------------------------------------------------------------------------------
Is there anything in their observations that you think could delay the action date specifically?
--------------------------------------------------------------------------------
Amar Sawhney, Ocular Therapeutix, Inc. - President, CEO & Chairman [24]
--------------------------------------------------------------------------------
Nothing that we can currently see. I think these as you know probably 90%-plus inspections have a 483. The question is what are the nature of the issues in the 483.
We think these are resolvable issues. And we have responses some already prepared and some being prepared to address them in a timely fashion.re-inspection needed going forward.
And then I guess what specifically gives you confidence that it's not going to happen? Because it seems like there is a number of things that were brought up on this 483.
--------------------------------------------------------------------------------
Amar Sawhney, Ocular Therapeutix, Inc. - President, CEO & Chairman [33]
--------------------------------------------------------------------------------
Yes, because most of the issues that are brought up on the 483 are not long-term type of issues. These are quality system and methodology type of things that are to be addressed by modifications of training procedures, documentation and in one case a test method that is a relatively short-term type of a test method. But Eric can comment a little on that.
--------------------------------------------------------------------------------
Eric Ankerud, Ocular Therapeutix, Inc. - EVP, Regulatory, Quality, and Compliance [34]
--------------------------------------------------------------------------------
In addition to that we have commercial product in our controlled inventory. And that was something FDA was looking for as part of this re-inspection as a sign that we are ready to go for a commercial launch.
Recent OCUL News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/12/2024 08:20:42 PM
- Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/09/2024 08:23:26 PM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/08/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/17/2024 08:12:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 01:03:53 PM
- Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study • GlobeNewswire Inc. • 06/13/2024 08:05:00 PM
- Ocular Therapeutix® to Host Investor Day on June 13, 2024 • GlobeNewswire Inc. • 06/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:28:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:26:14 PM
- Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/04/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:15:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 09:17:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:33:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 09:01:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 08:18:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/23/2024 08:16:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2024 08:22:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:20:40 PM
- Ocular Therapeutix™ Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2024 08:01:07 PM
- Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/07/2024 12:16:15 AM
- Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/06/2024 11:30:00 AM
- Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 • GlobeNewswire Inc. • 05/03/2024 11:30:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM